Hydroxychloroquine-d4 (sulfate)
(Synonyms: HCQ-d4 sulfate) 目录号 : GC47445An internal standard for the quantification of hydroxychloroquine
Cas No.:1854126-45-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Hydroxychloroquine-d4 (sulfate) is intended for use as an internal standard for the quantification of hydroxychloroquine by GC- or LC-MS. Hydroxychloroquine is an aminoquinoline with antimalarial, anti-inflammatory, and antiviral activities.1,2,3,4 It is active against the chloroquine-sensitive NF54 and D6 strains of P. falciparum (IC50s = 16.3 and 15 nM, respectively) but has decreased activity against chloroquine-resistant P. falciparum strains (IC50s = 422.7-1,735.3 nM).1 Hydroxychloroquine inhibits production of IL-22, IL-17A, and IL-6 induced by phorbol 12-myristate 13-acetate and ionomycin in peripheral blood mononuclear cells (PBMCs) isolated from healthy individuals or patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).5 It inhibits accumulation of sequestosome-1 (SQSTM1) puncta, a marker of autophagy, in mouse embryonic fibroblasts (MEFs) in a concentration-dependent manner.2 Hydroxychloroquine reduces viral titers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the culture supernatant of infected Vero E6 cells but does not reduce SARS-CoV-2 viral titers in an in vitro human airway epithelium model or the respiratory tract of infected cynomolgus macaques.4 Formulations containing hydroxychloroquine have been used in the prevention or treatment of malaria, as well as in the treatment of RA and SLE.
1.Delves, M., Plouffe, D., Scheurer, C., et al.The activities of current antimalarial drugs on the life cycle stages of Plasmodium: A comparative study with human and rodent parasitesPLoS Med.9(2)e1001169(2012) 2.Mauthe, M., Orhon, I., Rocchi, C., et al.Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusionAutophagy14(8)1435-1455(2018) 3.da Silva, J.C., Mariz, H.A., da Rocha, L.F., Jr., et al.Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patientsClinics (Sao Paulo)68(6)766-771(2013) 4.Maisonnasse, P., Guedj , J., Contreras, V., et al.Hydroxychloroquine use against SARS-CoV-2 infection in non-human primatesNature585(7826)584-587(2020) 5.Yi, J., Zhu, J., Wu, J., et al.Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesisProc. Natl. Acad. Sci. USA202017152(2020)
Cas No. | 1854126-45-6 | SDF | |
别名 | HCQ-d4 sulfate | ||
Canonical SMILES | CC(CCCN(CC)C([2H])([2H])C([2H])([2H])O)NC1=CC=NC2=CC(Cl)=CC=C21.O=S(O)(O)=O | ||
分子式 | C18H22D4ClN3O.H2SO4 | 分子量 | 438 |
溶解度 | Water: 100 mM | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.2831 mL | 11.4155 mL | 22.8311 mL |
5 mM | 0.4566 mL | 2.2831 mL | 4.5662 mL |
10 mM | 0.2283 mL | 1.1416 mL | 2.2831 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。